Literature DB >> 17508847

Effect of low-level laser therapy on hemorrhagic lesions induced by immune complex in rat lungs.

F Aimbire1, R A B Lopes-Martins, R Albertini, M T T Pacheco, H C Castro-Faria-Neto, P S L L Martins, J M Bjordal.   

Abstract

OBJECTIVE: The aim of this study was to investigate if low-level laser therapy (LLLT) can modulate formation of hemorrhagic lesions induced by immune complex. BACKGROUND DATA: There is a lack of information on LLLT effects in hemorrhagic injuries of high perfusion organs, and the relative efficacy of LLLT compared to anti-inflammatory drugs.
METHODS: A controlled animal study was undertaken with 49 male Wistar rats randomly divided into seven groups. Bovine serum albumin (BSA) i.v. was injected through the trachea to induce an immune complex lung injury. The study compared the effect of irradiation by a 650-nm Ga-Al-As laser with LLLT doses of 2.6 Joules/cm(2) to celecoxib, dexamethasone, and control groups for hemorrhagic index (HI) and myeloperoxide activity (MPO) at 24 h after injury.
RESULTS: The HI for the control group was 4.0 (95% CI, 3.7-4.3). Celecoxib, LLLT, and dexamethasone all induced significantly (p < 0.01) lower HI than control animals at 2.5 (95% CI, 1.9-3.1), 1.8 (95% CI, 1.2-2.4), and 1.5 (95% CI, 0.9-2.1), respectively, for all comparisons to control. Dexamethasone, but not celecoxib, induced a slightly, but significantly lower HI than LLLT (p = 0.04). MPO activity was significantly decreased in groups receiving celecoxib at 0.87 (95% CI, 0.63-1.11), dexamethasone at 0.50 (95% CI, 0.24-0.76), and LLLT at 0.7 (95% CI, 0.44-0.96) when compared to the control group, at 1.6 (95% CI, 1.34-1.96; p < 0.01), but there were no significant differences between any of the active treatments.
CONCLUSION: LLLT at a dose of 2.6 Joules/cm(2) induces a reduction of HI levels and MPO activity in hemorrhagic injury that is not significantly different from celecoxib. Dexamethasone is slightly more effective than LLLT in reducing HI, but not MPO activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17508847     DOI: 10.1089/pho.2006.1041

Source DB:  PubMed          Journal:  Photomed Laser Surg        ISSN: 1549-5418            Impact factor:   2.796


  10 in total

1.  Low-level laser therapy (LLLT) acts as cAMP-elevating agent in acute respiratory distress syndrome.

Authors:  Flávia Mafra de Lima; Leonardo M Moreira; A B Villaverde; Regiane Albertini; Hugo C Castro-Faria-Neto; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2010-12-24       Impact factor: 3.161

2.  Low-level laser therapy in different stages of rheumatoid arthritis: a histological study.

Authors:  Ana Carolina Araruna Alves; Paulo de Tarso Camillo de Carvalho; Marcio Parente; Murilo Xavier; Lucio Frigo; Flávio Aimbire; Ernesto Cesar Pinto Leal Junior; Regiane Albertini
Journal:  Lasers Med Sci       Date:  2012-04-27       Impact factor: 3.161

3.  ELECTROPHYSICAL AGENTS - Contraindications And Precautions: An Evidence-Based Approach To Clinical Decision Making In Physical Therapy.

Authors: 
Journal:  Physiother Can       Date:  2011-01-05       Impact factor: 1.037

4.  Adjunct low level laser therapy (LLLT) in a morbidly obese patient with severe COVID-19 pneumonia: A case report.

Authors:  Scott A Sigman; Soheila Mokmeli; Mariana A Vetrici
Journal:  Can J Respir Ther       Date:  2020-09-28

5.  Low level laser therapy (LLLT) decreases pulmonary microvascular leakage, neutrophil influx and IL-1beta levels in airway and lung from rat subjected to LPS-induced inflammation.

Authors:  F Aimbire; A P Ligeiro de Oliveira; R Albertini; J C Corrêa; C B Ladeira de Campos; J P Lyon; J A Silva; M S Costa
Journal:  Inflammation       Date:  2008-04-18       Impact factor: 4.092

6.  Infrared low-level diode laser on inflammatory process modulation in mice: pro- and anti-inflammatory cytokines.

Authors:  Thiago Y Fukuda; Maury M Tanji; Suélen R Silva; Maria N Sato; Hélio Plapler
Journal:  Lasers Med Sci       Date:  2012-11-24       Impact factor: 3.161

7.  Suppressive effect of low-level laser therapy on tracheal hyperresponsiveness and lung inflammation in rat subjected to intestinal ischemia and reperfusion.

Authors:  Flávia Mafra de Lima; Luana Vitoretti; Fernando Coelho; Regiane Albertini; Ana Cristina Breithaupt-Faloppa; Wothan Tavares de Lima; Flávio Aimbire
Journal:  Lasers Med Sci       Date:  2012-05-05       Impact factor: 3.161

8.  Red (660 nm) and infrared (830 nm) low-level laser therapy in skeletal muscle fatigue in humans: what is better?

Authors:  Patrícia de Almeida; Rodrigo Alvaro Brandão Lopes-Martins; Thiago De Marchi; Shaiane Silva Tomazoni; Regiane Albertini; João Carlos Ferrari Corrêa; Rafael Paolo Rossi; Guilherme Pinheiro Machado; Daniela Perin da Silva; Jan Magnus Bjordal; Ernesto Cesar Pinto Leal Junior
Journal:  Lasers Med Sci       Date:  2011-07-22       Impact factor: 3.161

9.  Superpulsed low-level laser therapy protects skeletal muscle of mdx mice against damage, inflammation and morphological changes delaying dystrophy progression.

Authors:  Ernesto Cesar Pinto Leal-Junior; Patrícia de Almeida; Shaiane Silva Tomazoni; Paulo de Tarso Camillo de Carvalho; Rodrigo Álvaro Brandão Lopes-Martins; Lucio Frigo; Jon Joensen; Mark I Johnson; Jan Magnus Bjordal
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

10.  A 57-Year-Old African American Man with Severe COVID-19 Pneumonia Who Responded to Supportive Photobiomodulation Therapy (PBMT): First Use of PBMT in COVID-19.

Authors:  Scott A Sigman; Soheila Mokmeli; Monica Monici; Mariana A Vetrici
Journal:  Am J Case Rep       Date:  2020-08-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.